CELESTIAL

The CELESTIAL study is a multicentre, retrospective study in Germany that investigates clinical experience with letermovir for CMV prophylaxis in hematology and oncology patients who underwent allogeneic hematopoietic cell transplantation between 2018 and 2021. Clinical as well as health-economic parameters are compared within a 48-week follow-up between the periods before and after the approval of letermovir in 2018. The study center in Frankfurt participated in the trial, while overall responsibility for the project was hold by the University Hospital Cologne.

This study is supported by an unrestricted research grant from MSD Sharp & Dohme GmbH (Germany).